205 related articles for article (PubMed ID: 24766386)
1. Latest progress in the identification of novel synthetic ligands for the cannabinoid CB2 receptor.
Han S; Chen JJ; Chen JZ
Mini Rev Med Chem; 2014 May; 14(5):426-43. PubMed ID: 24766386
[TBL] [Abstract][Full Text] [Related]
2. New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds.
Nimczick M; Decker M
ChemMedChem; 2015 May; 10(5):773-86. PubMed ID: 25820617
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
Vasiljevik T; Franks LN; Ford BM; Douglas JT; Prather PL; Fantegrossi WE; Prisinzano TE
J Med Chem; 2013 Jun; 56(11):4537-50. PubMed ID: 23631463
[TBL] [Abstract][Full Text] [Related]
4. Modern approaches to the development of synthetic cannabinoid receptor probes.
Saldaña-Shumaker SL; Grenning AJ; Cunningham CW
Pharmacol Biochem Behav; 2021 Apr; 203():173119. PubMed ID: 33508249
[TBL] [Abstract][Full Text] [Related]
5. Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.
Shi Y; Duan YH; Ji YY; Wang ZL; Wu YR; Gunosewoyo H; Xie XY; Chen JZ; Yang F; Li J; Tang J; Xie X; Yu LF
J Med Chem; 2017 Aug; 60(16):7067-7083. PubMed ID: 28726401
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update.
Morales P; Hernandez-Folgado L; Goya P; Jagerovic N
Expert Opin Ther Pat; 2016 Jul; 26(7):843-56. PubMed ID: 27215781
[TBL] [Abstract][Full Text] [Related]
7. Cryo-EM Structure of the Human Cannabinoid Receptor CB2-G
Xing C; Zhuang Y; Xu TH; Feng Z; Zhou XE; Chen M; Wang L; Meng X; Xue Y; Wang J; Liu H; McGuire TF; Zhao G; Melcher K; Zhang C; Xu HE; Xie XQ
Cell; 2020 Feb; 180(4):645-654.e13. PubMed ID: 32004460
[TBL] [Abstract][Full Text] [Related]
8. Contrasting effects of different cannabinoid receptor ligands on mouse ingestive behaviour.
Grey J; Terry P; Higgs S
Behav Pharmacol; 2012 Sep; 23(5-6):551-9. PubMed ID: 22772336
[TBL] [Abstract][Full Text] [Related]
9. CB2 cannabinoid receptor agonist selectively inhibits the mechanosensitivity of mucosal afferents in the guinea pig bladder.
Christie S; Zagorodnyuk V
Am J Physiol Renal Physiol; 2021 May; 320(5):F859-F865. PubMed ID: 33749323
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA.
Banister SD; Moir M; Stuart J; Kevin RC; Wood KE; Longworth M; Wilkinson SM; Beinat C; Buchanan AS; Glass M; Connor M; McGregor IS; Kassiou M
ACS Chem Neurosci; 2015 Sep; 6(9):1546-59. PubMed ID: 26134475
[TBL] [Abstract][Full Text] [Related]
11. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
Rempel V; Volz N; Hinz S; Karcz T; Meliciani I; Nieger M; Wenzel W; Bräse S; Müller CE
J Med Chem; 2012 Sep; 55(18):7967-77. PubMed ID: 22916707
[TBL] [Abstract][Full Text] [Related]
12. The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist.
Moir M; Lane S; Montgomery AP; Hibbs D; Connor M; Kassiou M
Eur J Med Chem; 2021 Jan; 210():113087. PubMed ID: 33321261
[TBL] [Abstract][Full Text] [Related]
13. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
[TBL] [Abstract][Full Text] [Related]
14. Identification of CB1/CB2 ligands from Zanthoxylum bungeanum.
Dossou KS; Devkota KP; Morton C; Egan JM; Lu G; Beutler JA; Moaddel R
J Nat Prod; 2013 Nov; 76(11):2060-4. PubMed ID: 24175626
[TBL] [Abstract][Full Text] [Related]
15. Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.
Yang P; Wang L; Feng R; Almehizia AA; Tong Q; Myint KZ; Ouyang Q; Alqarni MH; Wang L; Xie XQ
J Med Chem; 2013 Mar; 56(5):2045-58. PubMed ID: 23406429
[TBL] [Abstract][Full Text] [Related]
16. Structure-kinetic relationship studies of cannabinoid CB
Soethoudt M; Hoorens MWH; Doelman W; Martella A; van der Stelt M; Heitman LH
Biochem Pharmacol; 2018 Jun; 152():129-142. PubMed ID: 29574067
[TBL] [Abstract][Full Text] [Related]
17. Δ
Shang VC; Kendall DA; Roberts RE
Biochem Pharmacol; 2016 Nov; 120():63-71. PubMed ID: 27641813
[TBL] [Abstract][Full Text] [Related]
18. Modulation of l-α-lysophosphatidylinositol/GPR55 MAP kinase signalling by CB2 receptor agonists: identifying novel GPR55 inhibitors.
Anavi-Goffer S; Irving AJ; Ross RA
J Basic Clin Physiol Pharmacol; 2016 May; 27(3):303-10. PubMed ID: 27089417
[TBL] [Abstract][Full Text] [Related]
19. Effects of Cannabinoid Agonists and Antagonists on Sleep and Breathing in Sprague-Dawley Rats.
Calik MW; Carley DW
Sleep; 2017 Sep; 40(9):. PubMed ID: 28934522
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands.
Ragusa G; Bencivenni S; Morales P; Callaway T; Hurst DP; Asproni B; Merighi S; Loriga G; Pinna GA; Reggio PH; Gessi S; Murineddu G
ChemMedChem; 2018 Jun; 13(11):1102-1114. PubMed ID: 29575721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
